NURS 5315 UTA EXAM 2 EXAM(ACTUAL
EXAM) WITH CORRECT ACTUAL
QUESTIONS AND CORRECTLY WELL
DEFINED ANSWERS LATEST ALREADY
GRADED A+ 2026
Acute Lymphocytic Leukemia (ALL) - ANSWERS-Marked by
>30% lymphoblasts in blood or marrow
Most common in children
Survival rate decreases with age
CM: fever, pallor, bleeding, fatigue, lymphadenopathy,
infection, joint pain, splenomegaly, hepatomegaly, night
sweats, weight loss, anemia, thrombocytopenia, petechiae,
ecchymosis
Acute Myelogenous Leukemia (AML) - ANSWERS-Marked by
proliferation of immature myeloid cells, decreased
apoptosis, and lack of cellular differentiation
Most common in adults
,Remission is inversely related to age
CM: fever, pallor, bleeding, fatigue, lymphadenopathy,
infection, joint pain, splenomegaly, hepatomegaly, night
sweats, weight loss, anemia, thrombocytopenia, petechiae,
ecchymosis
Chronic Lymphocytic Leukemia (CLL) - ANSWERS-Malignant
transformation of B-lymphocytes
Increased occurrence over 40
Survival 10yrs or longer
CM: suppression of humoral immunity, increased infections
Chronic Myelogenous Leukemia (CML) - ANSWERS-Presence
of Philadelphia chromosome
Increased occurrence over 40
Bone marrow transplant may be curative
COX1 - ANSWERS-Prostaglandin of arachidonic pathway.
Provides gastroprotection, platelet aggregation,
fluid/electrolyte balance
, COX2 - ANSWERS-Prostaglandin of arachidonic pathway.
Responsible for pain, fever, renal protection, tissue repair,
reproduction development.
COX2 inhibitors- clinical implications - ANSWERS-Protect
gastric mucosa- prevent ulcers and bleeding. Removed from
market r/t cardiac events except for Celebrex. Can impair
renal function , monitor labs.
Arachidonic pathway purpose - ANSWERS-Synthesis of
prostaglandins
Non-selective NSAIDS - ANSWERS-Inhibit COX1 and COX2,
risk for gastric ulceration, GI bleeds, edema, renal
impairment
ASA - ANSWERS-Blocks COX1 and COX2, also inhibits
Thromboxane A2 and prostaglandins
Corticosteroids - ANSWERS-Inhibit phospholipase A2,
preventing formation of prostaglandins, thromboxane A2,
prostacyclin, and leukotrines
EXAM) WITH CORRECT ACTUAL
QUESTIONS AND CORRECTLY WELL
DEFINED ANSWERS LATEST ALREADY
GRADED A+ 2026
Acute Lymphocytic Leukemia (ALL) - ANSWERS-Marked by
>30% lymphoblasts in blood or marrow
Most common in children
Survival rate decreases with age
CM: fever, pallor, bleeding, fatigue, lymphadenopathy,
infection, joint pain, splenomegaly, hepatomegaly, night
sweats, weight loss, anemia, thrombocytopenia, petechiae,
ecchymosis
Acute Myelogenous Leukemia (AML) - ANSWERS-Marked by
proliferation of immature myeloid cells, decreased
apoptosis, and lack of cellular differentiation
Most common in adults
,Remission is inversely related to age
CM: fever, pallor, bleeding, fatigue, lymphadenopathy,
infection, joint pain, splenomegaly, hepatomegaly, night
sweats, weight loss, anemia, thrombocytopenia, petechiae,
ecchymosis
Chronic Lymphocytic Leukemia (CLL) - ANSWERS-Malignant
transformation of B-lymphocytes
Increased occurrence over 40
Survival 10yrs or longer
CM: suppression of humoral immunity, increased infections
Chronic Myelogenous Leukemia (CML) - ANSWERS-Presence
of Philadelphia chromosome
Increased occurrence over 40
Bone marrow transplant may be curative
COX1 - ANSWERS-Prostaglandin of arachidonic pathway.
Provides gastroprotection, platelet aggregation,
fluid/electrolyte balance
, COX2 - ANSWERS-Prostaglandin of arachidonic pathway.
Responsible for pain, fever, renal protection, tissue repair,
reproduction development.
COX2 inhibitors- clinical implications - ANSWERS-Protect
gastric mucosa- prevent ulcers and bleeding. Removed from
market r/t cardiac events except for Celebrex. Can impair
renal function , monitor labs.
Arachidonic pathway purpose - ANSWERS-Synthesis of
prostaglandins
Non-selective NSAIDS - ANSWERS-Inhibit COX1 and COX2,
risk for gastric ulceration, GI bleeds, edema, renal
impairment
ASA - ANSWERS-Blocks COX1 and COX2, also inhibits
Thromboxane A2 and prostaglandins
Corticosteroids - ANSWERS-Inhibit phospholipase A2,
preventing formation of prostaglandins, thromboxane A2,
prostacyclin, and leukotrines
